Atai Beckley Inc's pre-market stock price gains quickly narrowed from 70% to 30%; Eli Lilly said on Thursday it would acquire psychedelic drug developer AtaiBeckley ATAI.O for up to $3.8 billion, entering the race to develop psychedelic treatments for depression and other mental health disorders.